Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity.

ABSTRACT: Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this context. On the other hand, obesity is a known risk thromboembolic factor. In the clinical trials that led to the approval of DOAC for ischemic stroke prevention, patients with morbid obesity were underrepresented. The International Society of Thrombosis and Haemostasis suggests not using these drugs in morbid obese patients. Thus, the primary objectives of this study were to analyse the rates of mortality, thrombotic and haemorrhagic events in patients with morbid obesity. As secondary objectives, factors statistically associated with these events were analysed. Methods: multicentre retrospective study that incl

SUBMITTER: Navarro-Almenzar B 

PROVIDER: S-EPMC8603013 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature